1-(pyridine-3-yl)butan-2-one | 6302-10-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(pyridine-3-yl)butan-2-one
• 英文别名: 1-(pyridin-3-yl)butan-2-one；1-pyridin-3-yl-butan-2-one；1-(3-Pyridyl)-butan-2-on；3-Picolyl-ethyl-keton；1-pyridin-3-ylbutan-2-one
• CAS: 6302-10-9
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: WMTHSBOLQVKBQL-UHFFFAOYSA-N

物化性质

• 沸点：
  103-104 °C(Press: 2.53 Torr)
• 密度：
  1.054 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(pyridine-3-yl)butan-2-one 在 potassium carbonate 、 间氯过氧苯甲酸 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 生成 1-benzyl-2-ethyl-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  不含过渡金属的7-氮杂吲哚

  摘要：

  通过一锅合成法开发了一种新型的无过渡金属合成7-氮杂吲哚的方法，该方法涉及吡啶N-氧化物的胺化和分子内烯胺的形成。该方法的显着特征包括操作简单，反应条件温和，底物范围宽和容易获得的起始原料。

  DOI：

  10.1016/j.tet.2018.06.025
• 作为产物：
  描述：

  3-吡啶乙酸 、 丙酸酐 在 吡啶 作用下， 反应 6.0h， 以22%的产率得到1-(pyridine-3-yl)butan-2-one
  参考文献：
  名称：

  Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer

  摘要：

  DOI：

  10.1016/j.ejmech.2021.113733

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010099527A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制RNA含病毒，特别是丙型肝炎病毒（HCV）的化合物或药用可接受的盐、酯或前药，因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。
• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170320833A1

  公开（公告）日：2017-11-09

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和方法，用于治疗丙型肝炎病毒（HCV）感染。还公开了含有这些化合物的制药组合物和使用这些化合物治疗HCV感染的方法。
• [EN] NOVEL BENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
  申请人：ENANTA PHARM INC

  公开号：WO2013052369A1

  公开（公告）日：2013-04-11

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了式（I）的化合物，或其药学上可接受的盐、酯或前药：其抑制RNA含量的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者注射包含本发明化合物的制药组合物来治疗HCV感染的方法。
• N-Hydroxy-1,2-dihydro-2-oxo-5-(pyridinyl)-nicotinimidamide and their
  申请人：Sterling Drug Inc.

  公开号：US04305948A1

  公开（公告）日：1981-12-15

  N-Hydroxy-1-R.sub.1 -1,2-dihydro-2-oxo-5-PY-6-R-nicotinimidamides or pharmaceutically-acceptable acid-addition salts thereof, useful as cardiotonic agents, are prepared by reacting 1-R.sub.1 -1,2-dihydro-2-oxo-5-PY-6-R-nicotinonitriles with hydroxylamine and are converted by reaction with polyphosphoric acid to the corresponding cardiotonically useful 1-R.sub.1 -3-amino-5-PY-6-R-2(1H)-pyridinones, where R.sub.1 is hydrogen, lower-alkyl and lower-hydroxyalkyl, R is hydrogen or lower-alkyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents.

  N-羟基-1-R.sub.1-1,2-二氢-2-氧-5-PY-6-R-烟酰胺或其药物可接受的酸加合物，可用作心脏强心剂，通过将1-R.sub.1-1,2-二氢-2-氧-5-PY-6-R-烟酰腈与羟胺反应制备，然后通过与多聚磷酸反应转化为相应的有用的1-R.sub.1-3-氨基-5-PY-6-R-2（1H）-吡啶酮，其中R.sub.1是氢，低烷基和低羟基烷基，R是氢或低烷基，PY是4-或3-吡啶基或4-或3-吡啶基，具有一个或两个低烷基取代基。